5-α reductase inhibitors and prostate cancer prevention: Where do we turn now?

BMC Medicine

Volumn 9, Issue , 2011, Pages

  Hamilton, Robert J ^a,b   Freedland, Stephen J ^b,c,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c DURHAM VA MEDICAL CENTER   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; FINASTERIDE; PLACEBO; STEROID 5ALPHA REDUCTASE INHIBITOR; AZASTEROID;

ADULT; CANCER MORTALITY; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DRUG SAFETY; HUMAN; HUMAN TISSUE; MALE; NOTE; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TUMOR BIOPSY; DRUG APPROVAL; EDITORIAL; FOOD AND DRUG ADMINISTRATION; METHODOLOGY; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; UNITED STATES;

5-ALPHA REDUCTASE INHIBITORS; AZASTEROIDS; CHEMOPREVENTION; DRUG APPROVAL; FINASTERIDE; HUMANS; MALE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 80052867174     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/1741-7015-9-105     Document Type: Note

References (52)

1. American Cancer Society. Cancer Facts and Figures 2010. , http://www.cancer.org/acs/groups/content/@nho/documents/document/acspc-024113.pdf
2. Stokes ME, Black L, Benedict A, Roehrborn CG, Albertsen P. Long-term medical-care costs related to prostate cancer: estimates from linked SEER-Medicare data. Prostate Cancer Prostatic Dis 2010, 13:278-284. 10.1038/pcan.2010.5, 20212521.
3. Silberstein JL, Parsons JK. Prostate cancer prevention: concepts and clinical recommendations. Prostate Cancer Prostatic Dis 2010, 13:300-306. 10.1038/pcan.2010.18, 20567257.
4. Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM, Haapakoski J, Malila N, Rautalahti M, Ripatti S, Mäenpää H, Teerenhovi L, Koss L, Virolainen M, Edwards BK. Prostate cancer and supplementation with α-tocopherol and β-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst 1998, 90:440-446. 10.1093/jnci/90.6.440, 9521168.
5. Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, Marshall JR, Clark LC. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 2003, 91:608-612. 10.1046/j.1464-410X.2003.04167.x, 12699469.
6. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009, 301:39-51. 10.1001/jama.2008.864, 19066370.
7. Ma J, Stampfer MJ, Gann PH, Hough HL, Giovannucci E, Kelsey KT, Hennekens CH, Hunter DJ. Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomarkers Prev 1998, 7:385-390.
8. Raghow S, Hooshdaran MZ, Katiyar S, Steiner MS. Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res 2002, 62:1370-1376.
9. Mahmud SM, Franco EL, Turner D, Platt RW, Beck P, Skarsgard D, Tonita J, Sharpe C, Aprikian AG. Use of non-steroidal anti-inflammatory drugs and prostate cancer risk: a population-based nested case-control study. PLoS One 2011, 6:e16412. 10.1371/journal.pone.0016412, 3030588, 21297996.
10. van Adelsberg J, Gann P, Ko AT, Damber JE, Logothetis C, Marberger M, Schmitz-Drager BJ, Tubaro A, Harms CJ, Roehrborn C. The VIOXX in Prostate Cancer Prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups. Curr Med Res Opin 2007, 23:2063-2070. 10.1185/030079907X219526, 17651539.
11. Price D, Stein B, Sieber P, Tutrone R, Bailen J, Goluboff E, Burzon D, Bostwick D, Steiner M. Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial. J Urol 2006, 176:965-971. 10.1016/j.juro.2006.04.011, 16890670.
12. Taneja SS, Morton RA, Barnette G, Hancock M, Brawer M, Steiner M. Men with isolated high grade prostatic intraepithelial neoplasia (HGPIN) have a high risk of prostate cancer in long-term follow-up: results from a prospective multicenter, randomized, placebo-controlled prostate cancer prevention trial. J Urol 2011, 185:e484.
13. Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ. The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst 2008, 100:1511-1518. 10.1093/jnci/djn362, 18957682.
14. Chang SL, Harshman LC, Presti JC. Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey. J Clin Oncol 2010, 28:3951-3957. 10.1200/JCO.2009.27.9406, 2940393, 20679596.
15. Bonovas S, Filioussi K, Sitaras NM. Statin use and the risk of prostate cancer: a metaanalysis of 6 randomized clinical trials and 13 observational studies. Int J Cancer 2008, 123:899-904. 10.1002/ijc.23550, 18491405.
16. Gutt R, Tonlaar N, Kunnavakkam R, Karrison T, Weichselbaum RR, Liauw SL. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol 2010, 28:2653-2659. 10.1200/JCO.2009.27.3003, 20421534.
17. Hamilton RJ, Banez LL, Aronson WJ, Terris MK, Platz EA, Kane CJ, Presti JC, Amling CL, Freedland SJ. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer 2010, 116:3389-3398. 10.1002/cncr.25308, 20586112.
18. Ku JH, Jeong CW, Park YH, Cho MC, Kwak C, Kim HH. Relationship of statins to clinical presentation and biochemical outcomes after radical prostatectomy in Korean patients. Prostate Cancer Prostatic Dis 2011, 14:63-68. 10.1038/pcan.2010.39, 20938462.
19. National Cancer Institute Clinical Trials (PDQ): Statin Therapy Versus Placebo Prior to Prostatectomy. , http://www.cancer.gov/clinicaltrials/search/view?cdrid=582847&version=HealthProfessional&protocolsearchid=9130632
20. National Cancer Institute Clinical Trials (PDQ): Phase II Study of Atorvastatin Calcium and Celecoxib in Patients With Hormone-Dependent Prostate-Specific Antigen Progression After Local Therapy for Prostate Cancer. , http://www.cancer.gov/clinicaltrials/search/view?cdrid=636488&version=HealthProfessional&protocolsearchid=9130632
21. Walsh PC, Madden JD, Harrod MJ, Goldstein JL, MacDonald PC, Wilson JD. Familial incomplete male pseudohermaphroditism, type 2: decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med 1974, 291:944-949. 10.1056/NEJM197410312911806, 4413434.
22. Petrow V, Padilla GM, Mukherji S, Marts SA. Endocrine dependence of prostatic cancer upon dihydrotestosterone and not upon testosterone. J Pharm Pharmacol 1984, 36:352-353.
23. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA, . Medical Therapy of Prostatic Symptoms (MTOPS) Research Group The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003, 349:2387-2398. 10.1056/NEJMoa030656, 14681504, Medical Therapy of Prostatic Symptoms (MTOPS) Research Group.
24. Roehrborn CG, Barkin J, Siami P, Tubaro A, Wilson TH, Morrill BB, Gagnier RP. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial. BJU Int 2011, 107:946-954. 10.1111/j.1464-410X.2011.10124.x, 21332630.
25. Dorsam J, Altwein J. 5α-reductase inhibitor treatment of prostatic diseases: background and practical implications. Prostate Cancer Prostatic Dis 2009, 12:130-136. 10.1038/pcan.2008.56, 19030020.
26. Becher E, Roehrborn CG, Siami P, Gagnier RP, Wilson TH, Montorsi F. The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study. Prostate Cancer Prostatic Dis 2009, 12:369-374. 10.1038/pcan.2009.37, 19901936.
27. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003, 349:215-224. 10.1056/NEJMoa030660, 12824459.
28. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS, . REDUCE Study Group Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010, 362:1192-1202. 10.1056/NEJMoa0908127, 20357281, REDUCE Study Group.
29. Albertsen P, Hanley JA, Fine BA. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005, 293:2095-2101. 10.1001/jama.293.17.2095, 15870412.
30. Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, Feng Z, Wood DP, Eastham JA, Yossepowitch O, Rabah DM, Kattan MW, Yu C, Klein EA, Stephenson AJ. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011, 185:869-875. 10.1016/j.juro.2010.10.057, 21239008.
31. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994, 271:368-374. 10.1001/jama.271.5.368, 7506797.
32. Lucia MS, Darke AK, Goodman PJ, La Rosa FG, Parnes HL, Ford LG, Coltman CA, Thompson IM. Pathologic characteristics of cancers detected in the Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer Prev Res 2008, 1:167-173.
33. US Food and Drug Administration: December 1, 2010 Meeting of the Oncologic Drugs Advisory Committee. FDA core presentation: NDA 020180/s034: Proscar (finasteride 5 mg tablet). , http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM236786.pdf
34. Berglund RK, Masterson TA, Vora KC, Eggener SE, Eastham JA, Guillonneau BD. Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol 2008, 180:1964-1968. 10.1016/j.juro.2008.07.051, 2919316, 18801515.
35. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010, 28:1117-1123. 10.1200/JCO.2009.26.0133, 2834465, 20124165.
36. Kulkarni GS, Al-Azab R, Lockwood G, Toi A, Evans A, Trachtenberg J, Jewett MA, Finelli A, Fleshner NE. Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol 2006, 175:505-509. 10.1016/S0022-5347(05)00236-3, 16406982.
37. Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, Lucia MS, Parnes HL, Coltman CA. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006, 98:1128-1133. 10.1093/jnci/djj307, 16912265.
38. Thompson IM, Tangen CM, Goodman PJ, Lucia MS, Parnes HL, Lippman SM, Coltman CA. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol 2007, 177:1749-1752. 10.1016/j.juro.2007.01.071, 17437804.
39. Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA, Thompson IM. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res 2008, 1:174-181.
40. Hamilton RJ, Kahwati LC, Kinsinger LS. Knowledge and use of finasteride for the prevention of prostate cancer. Cancer Epidemiol Biomarkers Prev 2010, 19:2164-2171. 10.1158/1055-9965.EPI-10-0082, 20699373.
41. GSK Statement on Avodart (dutasteride) for prostate cancer risk reduction. , http://www.gsk.com/media/pressreleases/2011/2011_pressrelease_10043.htm
42. Zeliadt SB, Etzioni RD, Penson DF, Thompson IM, Ramsey SD. Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. Am J Med 2005, 118:850-857. 10.1016/j.amjmed.2005.03.001, 16084177.
43. Grover S, Lowensteyn I, Hajek D, Trachtenberg J, Coupal L, Marchand S. Do the benefits of finasteride outweigh the risks in the prostate cancer prevention trial?. J Urol 2006, 175:934-938. 10.1016/S0022-5347(05)00424-6, 16469585.
44. Earnshaw SR, McDade CL, Black LK, Bell CF, Kattan MW. Cost effectiveness of 5-α reductase inhibitors for the prevention of prostate cancer in multiple patient populations. Pharmacoeconomics 2010, 28:489-505. 10.2165/11531780-000000000-00000, 20196623.
45. Reed SD, Scales CD, Stewart SB, Sun J, Moul JW, Schulman KA, Xu J. Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer. J Urol 2011, 185:841-847. 10.1016/j.juro.2010.10.078, 21239023.
46. Vickers AJ, Savage CJ, Lilja H. Finasteride to prevent prostate cancer: should all men or only a high-risk subgroup be treated?. J Clin Oncol 2010, 28:1112-1116. 10.1200/JCO.2009.23.5572, 2834464, 20124185.
47. Svatek RS, Lee JJ, Roehrborn CG, Lippman SM, Lotan Y. Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis. Cancer 2008, 112:1058-1065. 10.1002/cncr.23276, 18186497.
48. Svatek RS, Lotan Y. Cost utility of prostate cancer chemoprevention with dutasteride in men with an elevated prostate specific antigen. Cancer Prev Res (Phila) 2011, 4:277-283.
49. National Cancer Institute Clinical Trials (PDQ): Finasteride Challenge. , http://www.cancer.gov/clinicaltrials/search/view?cdrid=695783&version=HealthProfessional&protocolsearchid=9180532
50. National Cancer Institute Clinical Trials (PDQ): A Trial of PROSCAR (Finasteride) Versus Placebo in Men With an Initial Negative Prostate Biopsy. , http://www.cancer.gov/clinicaltrials/search/view?cdrid=656830&version=HealthProfessional&protocolsearchid=9180532
51. National Cancer Institute Clinical Trials PDQ: Prevention of Prostate Cancer With Dutasteride in Case of High Grade PIN Neoplasia. , http://www.cancer.gov/clinicaltrials/search/view?cdrid=624271&version=HealthProfessional&protocolsearchid=9180527
52. Fleshner NE, Lucia MS, Melich K, Nandy IM, Black L, Rittmaster RS. Effect of dutasteride on prostate cancer progression and cancer diagnosis on rebiopsy in the REDEEM active surveillance study [abstract 2]. J Clin Oncol 2011, 29(Suppl 7).